Clinical trials: Obstructive Lung Disease
Chronic Obstructive Pulmonary Diseases
The Role of Ambulatory Oxygen in Improving the Effectiveness of Pulmonary Rehabilitation for COPD Patients
Pulmonary rehabilitation (PR) is an exercise program tailored for patients with chronic lung disease that is a core part of the management of patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT02707770
- Testing
- Pulmonary Rehabilitation
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Imperial College Healthcare NHS Trust
Asthma
A Study of 2 Doses of MAP0010 in Adult Asthmatics
The purpose of this study is to examine the blood levels of two doses of MAP0010 (a corticosteroid) and two doses of an approved corticosteroid in adult asthma and safety with twice daily dosing over 7 days.
- Trial name
- P202 (NCT00554970)
- Testing
- MAP0010 low dose, MAP0010 high dose, Budesonide inhalation suspension 0.25mg
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Allergan
Immune Mediated Anemia, Immune Mediated Thrombocytopenia
Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias
Background: People who have a blood stem cell transplant can sometimes develop cytopenia. This means that their levels of one or more types of blood cell, such as the red cells or platelets, are lower than they should be.
- Conditions
- Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
- Trial name
- NCT05502783
- Testing
- fostamatinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung function in subjects with COPD and a Low Peak…
- Trial name
- NCT03095456
- Testing
- Revefenacin, Spiriva Handihaler®
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Mylan Inc.
Chronic Obstructive Pulmonary Disease, COPD
Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.
The purpose of this study is to investigate the effect of combined treatment with Symbicort and Spiriva, in terms of improvement of lung function, symptoms and inflammatory markers, in patients with severe COPD.
- Trial name
- NCT00496470
- Testing
- Symbicort (budesonide/formoterol turbuhaler 320/9ug), Spiriva (tiotropium bromide 18ug)
- Where
- 93 sites in Australia, Canada and 7 more
- Volunteers
- 660 people
- Sponsor
- AstraZeneca
COPD
A Study for the Assessment of the Benefits of a Novel Mesh Nebulizer in the Treatment of Patients With Stable COPD
Jet nebulizers have been the standard delivery system for aerosolized medications commonly prescribed to Chronic Obstructive Pulmonary Disease (COPD) patients; however, these devices are inefficient and require an external…
- Trial name
- NCT03933462
- Testing
- InnoSpire Go, Jet Nebulizer
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Philips Respironics
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol
The study will evaluate bioavailability, pharmacokinetics, safety, and tolerability of budesonide, glycopyrronium and formoterol (BGF) metered dose inhaler (MDI) formulated with 3 different propellants: Propellant 1 (Treatment A…
- Trial name
- NCT04600505
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
The purpose of the study is to provide long term safety data of NVA237. This study will assess the safety and tolerability of a single dose strength of NVA237.
- Trial name
- NCT01697696
- Testing
- NVA237, Long-acting beta 2-agonist (LABA)
- Where
- 61 sites in United States
- Volunteers
- 511 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to…
- Trial name
- NCT01815424
- Testing
- CP-690,550
- Where
- 24 sites in China, South Korea and 1 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies.
- Trial name
- TERRANOVA (NCT02155660)
- Testing
- Benralizumab Arm A, Benralizumab Arm B, Benralizumab Arm C
- Where
- 356 sites in United States, Argentina and 24 more
- Volunteers
- 2,255 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks
The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticanse propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide (125mcg) once-daily to…
- Trial name
- NCT01772134
- Testing
- Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg
- Where
- 73 sites in United States, Canada and 2 more
- Volunteers
- 617 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
The objectives of this trial are primarily to evaluate the efficacy and safety of BI 655066/ABBV-066 (risankizumab) as compared to placebo over a 24-week treatment period in severe asthma patients.
- Trial name
- NCT02443298
- Testing
- risankizumab
- Where
- 65 sites in United States, Belgium and 8 more
- Volunteers
- 214 people
- Sponsor
- AbbVie
Asthma
Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART)
Vitamin D supplementation given to pregnant women will prevent asthma in their offspring and children.
- Trial name
- VDAART (NCT00920621)
- Testing
- Vitamin D 3 cholecalciferol, Vitamin D3
- Where
- 3 sites in United States
- Volunteers
- 876 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Pulmonary Disease, Chronic Obstructive
Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations
This was a retrospective cohort design using administrative claims data from Jan 1, 2003 through Sep 30, 2007, representing the years of available data, were used for this study.
- Trial name
- NCT01381406
- Testing
- TIO, TIO+FSC
- Volunteers
- 3,333 people
- Sponsor
- GlaxoSmithKline
Healthy, Pulmonary Disease, Chronic Obstructive
Relative Bioavailability of of Olodaterol and Ketoconazole
This clinical trial is intended to investigate a possible effect of the p-gp inhibitor ketoconazole on the bioavailability of olodaterol
- Trial name
- NCT01153711
- Testing
- BI 1744, Ketoconazole
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Asthma
A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)
This was a 2-part study in participants with allergen-induced asthma. It included a procedural pilot component (Part 1). Part 1 tested the key procedures and timing of Part 2; no study drug was administered during Part 1.
- Trial name
- NCT01343407
- Testing
- MK-1029 10 mg, MK-1029 100 mg
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils
A multi-center, randomized, open-label, parallel-group, repeat dose study in asthma patients with elevated eosinophils. Eligible subjects will receive 3 doses (28 days apart) of mepolizumab given intravenous (IV) or…
- Trial name
- NCT01366521
- Testing
- Mepolizumab
- Where
- 11 sites in United States, Estonia and 2 more
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Severe Asthma
Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
The investigators will measure different cytokines in the sputum (interleukin ((IL))-3, granulocyte-macrophage colony-stimulating factor ((GM-CSF)), IL5, IL-13, IL-33, IL-4, IL-25 thymic stromal lymphopoietin ((TSLP)) and…
- Trial name
- NCT04520165
- Where
- Belgium
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Liege
Asthma
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma…
- Trial name
- NCT03186209
- Testing
- Benralizumab
- Where
- 79 sites in China, Philippines and 2 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Diabetes, Asthma
Integrated Care (IC) Models for Patient-Centered Outcomes
Multiple chronic conditions (MCC) are widely recognized as the U.S. public health challenge of the 21st century. These physical and behavioral health conditions take a large toll on those living with chronic diseases, including…
- Conditions
- Diabetes, Asthma, Chronic Obstructive Pulmonary Disease, Hypertension
- Trial name
- IC (NCT03451630)
- Testing
- High-Touch, High-Tech, Optimal Discharge Planning
- Where
- United States
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.